Elevated galectin-3 precedes the development of CKD

Journal of the American Society of Nephrology

Volumn 24, Issue 9, 2013, Pages 1470-1477

  O'Seaghdha, Conall M ^a,b,c,d   Hwang, Shih Jen ^a,b   Ho, Jennifer E ^a,b,c   Vasan, Ramachandran S ^a,b,e   Levy, Daniel ^a,b   Fox, Caroline S ^a,b,c  

^a FRAMINGHAM HEART STUDY   (United States)

^b Center for Population Research   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BEAUMONT HOSPITAL   (Ireland)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GALECTIN 3;

ADULT; ALBUMINURIA; ARTICLE; CHRONIC KIDNEY DISEASE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 84884310000     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2012090909     Document Type: Article

References (70)

1. Coresh J, Selvin E, Stevens LA,Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS: Prevalence of chronic kidney disease in the United States. JAMA 298: 2038-2047, 2007
2. Zhang QL, Rothenbacher D: Prevalence of chronic kidney disease in population-based studies: Systematic review. BMC Public Health 8: 117, 2008
3. Chadban SJ, Briganti EM, Kerr PG, Dunstan DW, Welborn TA, Zimmet PZ, Atkins RC: Prevalence of kidney damage in Australian adults: The AusDiab kidney study.JAmSocNephrol 14[Suppl 2]: S131-S138, 2003
4. Chen J, Wildman RP, Gu D, Kusek JW, Spruill M, Reynolds K, Liu D, Hamm LL, Whelton PK, He J: Prevalence of decreased kidney function inChinese adults aged 35 to 74 years. Kidney Int 68: 2837-2845, 2005
5. Perkovic V, Cass A, Patel AA, Suriyawongpaisal P, Barzi F, Chadban S, Macmahon S, Neal B; InterASIA Collaborative Group: High prevalence of chronic kidney disease in Thailand. Kidney Int 73: 473-479, 2008
6. Tanaka H, Shiohira Y, Uezu Y, Higa A, Iseki K: Metabolic syndrome and chronic kidney disease in Okinawa, Japan. Kidney Int 69: 369-374, 2006
7. McClellan WM, Flanders WD: Risk factors for progressive chronic kidney disease. J Am Soc Nephrol 14[Suppl 2]: S65-S70, 2003
8. Muntner P, Vupputuri S, Coresh J, Uribarri J, Fox CS: Metabolic abnormalities are present in adults with elevated serumcystatin C. Kidney Int 76: 81-88, 2009
9. Hsu CY, McCulloch CE, Curhan GC: Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: Results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 13: 504-510, 2002
10. Ensrud KE, Lui LY, Taylor BC, Ishani A, ShlipakMG, Stone KL,Cauley JA, Jamal SA, Antoniucci DM, Cummings SR; Osteoporotic Fractures Research Group: Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med 167: 133-139, 2007
11. Fried LF, Shlipak MG, Crump C, Bleyer AJ, Gottdiener JS, Kronmal RA, Kuller LH, Newman AB: Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J AmColl Cardiol 41: 1364-1372, 2003
12. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, Salem DN, Levey AS, Sarnak MJ: Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: A pooled analysis of community-based studies. J Am Soc Nephrol 15: 1307-1315, 2004
13. de Zeeuw D, Ramjit D, Zhang Z, Ribeiro AB, Kurokawa K, Lash JP, Chan J, Remuzzi G, Brenner BM, Shahinfar S: Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: A post hoc analysis of RENAAL. Kidney Int 69: 1675-1682, 2006
14. Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G: Renoprotective properties of ACEinhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354: 359-364, 1999
15. Makino H, Nakamura Y, Wada J: Remission and regression of diabetic nephropathy. Hypertens Res 26: 515-519, 2003
16. de Boer RA, Yu L, van Veldhuisen DJ: Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep 7: 1-8, 2010
17. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP, Schroen B, André S, Crijns HJ, Gabius HJ, Maessen J, Pinto YM: Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110: 3121-3128, 2004
18. Liu YH,D'AmbrosioM, Liao TD, PengH, RhalebNE, Sharma U, André S, Gabius HJ, CarreteroOA:N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol 296: H404-H412, 2009
19. Hsu DK, Dowling CA, Jeng KC, Chen JT, Yang RY, Liu FT: Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma. Int J Cancer 81: 519-526, 1999
20. Henderson NC, Mackinnon AC, Farnworth SL, Poirier F, Russo FP, Iredale JP, Haslett C, Simpson KJ, Sethi T: Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci U S A 103: 5060-5065, 2006
21. Nishi Y, Sano H, Kawashima T, Okada T, Kuroda T, Kikkawa K, Kawashima S, TanabeM, Goto T,Matsuzawa Y, Matsumura R, Tomioka H, Liu FT, Shirai K: Role of galectin-3 in human pulmonary fibrosis. Allergol Int 56: 57-65, 2007
22. Dang Z, MacKinnon A, Marson LP, Sethi T: Tubular atrophy and interstitial fibrosis after renal transplantation is dependent on galectin-3. Transplantation 93: 477-484, 2012
23. Henderson NC, Mackinnon AC, Farnworth SL, Kipari T, Haslett C, Iredale JP, Liu FT, Hughes J, Sethi T: Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 172: 288-298, 2008
24. Okamura DM, Pasichnyk K, Lopez-Guisa JM, Collins S, Hsu DK, Liu FT, Eddy AA: Galectin-3 preserves renal tubules and modulates extracellular matrix remodeling in progressive fibrosis. Am J Physiol Renal Physiol 300: F245-F253, 2011
25. Rodríguez-Iturbe B, Johnson RJ, Herrera-Acosta J Tubulointerstitial damage and progression of renal failure. Kidney Int Suppl S82-S86, 2005
26. Tang WH, Shrestha K, Shao Z, Borowski AG, Troughton RW, Thomas JD, Klein AL: Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol 108: 385-390, 2011
27. Ho JE, Liu C, Lyass A, Courchesne P, PencinaMJ, Vasan RS, LarsonMG, Levy D: Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol 60: 1249-1256, 2012
28. Lok DJ, Van Der Meer P, de la Porte PW, Lipsic E, Van Wijngaarden J, Hillege HL, van Veldhuisen DJ: Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 99: 323-328, 2010
29. de Boer RA, van Veldhuisen DJ, Gansevoort RT, Muller Kobold AC, van Gilst WH, Hillege HL, Bakker SJ, van der Harst P: The fibrosis marker galectin-3 and outcome in the general population. J Intern Med 272: 55-64, 2012
30. de Boer RA, Lok DJ, Jaarsma T, van der Meer P, Voors AA, Hillege HL, van Veldhuisen DJ: Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 43: 60-68, 2011
31. de Boer RA, van Veldhuisen DJ, Gansevoort RT, Muller Kobold AC, van Gilst WH, Hillege HL, Bakker SJ, van der Harst P: The fibrosis marker galectin-3 and outcome in the general population: data from PREVEND. J InternMed272: 55-64, 2012
32. van Kimmenade RR, Januzzi JL Jr, Ellinor PT, Sharma UC, Bakker JA, Low AF, Martinez A, Crijns HJ, MacRae CA, Menheere PP, Pinto YM: Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J AmColl Cardiol 48: 1217-1224, 2006
33. de Filippi C, Christenson RH, Shah R, Bhardwaj A, Januzzi JL: Clinical validation of a novel assay for galectin-3 for risk assessment in acutely destabilized heart failure [Abstract]. J Cardiac Fail 15(Suppl): S9, 2009
34. Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR, Januzzi JL: Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail 12: 826-832, 2010
35. Ueland T, Aukrust P, Broch K, Aakhus S, Skårdal R, Muntendam P, Gullestad L: Galectin-3 in heart failure: High levels are associated with all-cause mortality. Int J Cardiol 150: 361-364, 2011
36. Fox CS, Gona P, Larson MG, Selhub J, Tofler G, Hwang SJ, Meigs JB, Levy D, Wang TJ, Jacques PF, Benjamin EJ, Vasan RS: A multi-marker approach to predict incident CKD and microalbuminuria. J Am Soc Nephrol 21: 2143-2149, 2010
37. Terata S, KikuyaM, SatohM,Ohkubo T, Hashimoto T, Hara A, Hirose T, Obara T, Metoki H, Inoue R, Asayama K, Kanno A, Totsune K, Hoshi H, Satoh H, Sato H, Imai Y: Plasma renin activity and the aldosterone-torenin ratio are associated with the development of chronic kidney disease: the Ohasama Study. J Hypertens 30: 1632-1638, 2012
38. Wollesen F, Brattström L, Refsum H, Ueland PM, Berglund L, Berne C: Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. Kidney Int 55: 1028-1035, 1999
39. Veldman BA, Vervoort G, Blom H, Smits P: Reduced plasma total homocysteine concentrations in type 1 diabetesmellitus is determined by increased renal clearance. Diabet Med 22: 301-305, 2005
40. Wesson DE, Simoni J, Broglio K, Sheather S: Acid retention accompanies reducedGFR in humans and increases plasmalevels of endothelin and aldosterone. Am J Physiol Renal Physiol 300: F830-F837, 2011
41. Winocour PH, Waldek S, Baker R: Relationships between renin, aldosterone, blood pressure and renal function in hypertensive insulindependent diabetes mellitus. Diabetes Res Clin Pract 7: 99-108, 1989
42. Roldán J,Morillas P, Castillo J, AndradeH,Guillén S, NúñezD,Quiles J, Bertomeu V: Plasma aldosterone and glomerular filtration in hypertensive patients with preserved renal function. Rev Esp Cardiol 63: 103-106, 2010
43. Dumic J, Dabelic S, Flögel M: Galectin-3: an open-ended story. Biochim Biophys Acta 1760: 616-635, 2006
44. Nieminen J, Kuno A, Hirabayashi J, Sato S: Visualization of galectin-3 oligomerization on the surface of neutrophils and endothelial cells using fluorescence resonance energy transfer. J Biol Chem282: 1374-1383, 2007
45. Ochieng J, Furtak V, Lukyanov P: Extracellular functions of galectin-3. Glycoconj J 19: 527-535, 2004
46. Iacobini C, Menini S, Oddi G, Ricci C, Amadio L, Pricci F, Olivieri A, SorciniM, DiMario U, Pesce C, Pugliese G: Galectin-3/AGE-receptor 3 knockout mice show accelerated AGE-induced glomerular injury: Evidence for a protective role of galectin-3 as an AGE receptor. FASEB J 18: 1773-1775, 2004
47. Bullock SL, Johnson TM, Bao Q, Hughes RC, Winyard PJ, Woolf AS: Galectin-3 modulates ureteric bud branching in organ culture of the developing mouse kidney. J Am Soc Nephrol 12: 515-523, 2001
48. Winyard PJ, Bao Q, Hughes RC, Woolf AS: Epithelial galectin-3 during human nephrogenesis and childhood cystic diseases. J Am Soc Nephrol 8: 1647-1657, 1997
49. Nishiyama J, Kobayashi S, Ishida A, Nakabayashi I, Tajima O, Miura S, Katayama M, Nogami H: Up-regulation of galectin-3 in acute renal failure of the rat. Am J Pathol 157: 815-823, 2000
50. Pugliese G, Pricci F, Iacobini C, Leto G, Amadio L, Barsotti P, Frigeri L, Hsu DK, Vlassara H, Liu FT, Di Mario U: Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice. FASEB J 15: 2471-2479, 2001
51. Henderson NC, Sethi T: The regulation of inflammation by galectin-3. Immunol Rev 230: 160-171, 2009
52. Sasaki S, Bao Q, Hughes RC: Galectin-3 modulates rat mesangial cell proliferation and matrix synthesis during experimental glomerulonephritis induced by anti-Thy1.1 antibodies. J Pathol 187: 481-489, 1999
53. Maeda N, Kawada N, Seki S, Arakawa T, Ikeda K, Iwao H, Okuyama H, Hirabayashi J, Kasai K, Yoshizato K: Stimulation of proliferation of rat hepatic stellate cells by galectin-1 and galectin-3 through different intracellular signaling pathways. J Biol Chem 278: 18938-18944, 2003
54. Lippert E, Falk W, Bataille F, Kaehne T,Naumann M, GoekeM, Herfarth H, Schoelmerich J, Rogler G: Soluble galectin-3 is a strong, colonic epithelial-cell-derived, lamina propria fibroblast-stimulating factor. Gut 56: 43-51, 2007
55. Weigert J, Neumeier M, Wanninger J, Bauer S, Farkas S, Scherer MN, Schnitzbauer A, Schäffler A, Aslanidis C, Schölmerich J, Buechler C: Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes. J Clin Endocrinol Metab 95: 1404-1411, 2010
56. Glinsky VV, Raz A: Modified citrus pectin anti-metastatic properties: One bullet, multiple targets. Carbohydr Res 344: 1788-1791, 2009
57. Kolatsi-Joannou M, Price KL, Winyard PJ, Long DA: Modified citrus pectin reduces galectin-3 expression and disease severity in experimental acute kidney injury. PLoS ONE 6: e18683, 2011
58. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP: An investigation of coronary heart disease in families. The Framingham offspring study. Am J Epidemiol 110: 281-290, 1979
59. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann InternMed 150: 604-612, 2009
60. Rifkin DE, Shlipak MG, Katz R, Fried LF, Siscovick D, Chonchol M, Newman AB, Sarnak MJ: Rapid kidney function decline and mortality risk in older adults. Arch Intern Med 168: 2212-2218, 2008
61. Shlipak MG, Katz R, Kestenbaum B, Siscovick D, Fried L, Newman A, Rifkin D, Sarnak MJ: Rapid decline of kidney function increases cardiovascular risk in the elderly. J AmSocNephrol 20: 2625-2630, 2009
62. FoxCS, LarsonMG, Leip EP,Culleton B,Wilson PW, LevyD: Predictors of new-onset kidney disease in a community-based population. JAMA 291: 844-850, 2004
63. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 39[Suppl 1]: S1-S266, 2002
64. Hsu CC, Brancati FL, Astor BC, Kao WH, Steffes MW, Folsom AR, Coresh J: Blood pressure, atherosclerosis, and albuminuria in 10,113 participants in the atherosclerosis risk in communities study. J Hypertens 27: 397-409, 2009
65. Culleton BF, LarsonMG, Parfrey PS, KannelWB, LevyD: Proteinuria as a risk factor for cardiovascular disease and mortality in older people: A prospective study. Am J Med 109: 1-8, 2000
66. Christenson RH, Duh SH,Wu AH, Smith A, Abel G, deFilippi CR,Wang S, Adourian A, Adiletto C, Gardiner P: Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure. Clin Biochem 43: 683-690, 2010
67. O'Seaghdha CM, Lyass A,Massaro JM,Meigs JB, Coresh J,D'Agostino RB Sr, Astor BC, Fox CS: A risk score for chronic kidney disease in the general population. Am J Med 125: 270-277, 2012
68. O'Seaghdha CM, Hwang SJ, Upadhyay A,Meigs JB, Fox CS: Predictors of incident albuminuria in the Framingham Offspring cohort. Am J Kidney Dis 56: 852-860, 2010
69. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS: Evaluating the added predictive ability of a newmarker: From area under the ROC curve to reclassification and beyond. StatMed 27: 157-172; discussion 207-112, 2008
70. Pencina MJ, D'Agostino RB Sr, Steyerberg EW: Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 30: 11-21, 2011